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Background: Basal-like breast cancer is a heterogeneous disease characterized by the expression of basal cell
markers, no estrogen or progesterone receptor expression and a lack of HER2 ov erexpression. Recent studies have
linked activation of the Wnt/β-catenin pathway, and its downstream target, Myc, to basal-like breast cancer.
Transgenic mice K5ΔNβcat previously generated by our team present a constitutive activation of Wnt/β-catenin
signaling in the basal myoepithelial cell layer, resulting in focal mammary hyperplasias that progress to invasive
carcinomas. Mammary lesions developed by K5ΔNβcat mice consist essentially of basal epithelial cells that, in
contrast to mammary myoepithelium, do not express smooth muscle markers.
Methods: Microarray analysis was used to compare K5ΔNβcat mouse tumors to human breast tumors, mammary
cancer cell lines and the tumors developed in other mouse models. Cre-Lox approach was employed to delete Myc
from the mammary basal cell layer of K5ΔNβcat mice. Stem cell amplification in K5ΔNβcat mouse mammary
epithelium was assessed with 3D-culture and transplantation assays.
Results: Histological and microarray analyses of the mammary lesions of K5ΔNβcat females revealed their high
similarity to a subset of basal-like human breast tumors with squamous differentiation. As in human basal-like
carcinomas, the Myc pathway appeared to be activated in the mammary lesions of K5ΔNβcat mice. We found that
a basal cell population with stem/progenitor characteristics was amplified in K5ΔNβcat mouse preneoplastic glands.
Finally, the deletion of Myc from the mammary basal layer of K5ΔNβcat mice not only abolished the regenerative
capacity of basal epithelial cells, but, in addition, completely prevented the tumorigenesis.
Conclusions: These results strongly indicate that β-catenin-induced stem cell amplification and tumorigenesis rely
ultimately on the Myc pathway activation and reinforce the hypothesis that basal stem/progenitor cells may be at
the origin of a subset of basal-like breast tumors.
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Microarray gene expression profiling of human primary
breast tumors has identified five main cancer subtypes:
luminal A and B, Her-2+, basal-like and normal-like
[1-3]. In the last years, additional molecular subtypes
have emerged including claudin-low and apocrine tu-
mors [4,5]. The basal-like subtype, accounts for 15 to
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reproduction in any medium, provided the orexpression of mammary basal cell markers, such as kera-
tins 5 and 14 (K5 and K14 respectively) and the tran-
scription factor p63. Basal-like tumors often exhibit poor
differentiation and higher rates of proliferation and are
frequently assimilated to triple-negative tumors, as nei-
ther express estrogen receptors (ER) nor progesterone
receptors and both lack HER2 overexpression [1]. Meta-
plastic carcinomas, characterized by the differentiation
of cancer cells towards squamous epithelium or mesen-
chymal elements, form part of the spectrum of basal-like
tumors [6].
The transcription factor proto-oncogene Myc regulates
the expression of many genes involved in the control ofal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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overexpression due to gene amplification or transcrip-
tional regulation is commonly associated with human
cancer. In breast cancer, Myc deregulation is associated
with poor outcome [8] and recent studies have shown
that Myc expression is particularly elevated in the basal-
like (or triple-negative) subtype [9-11]. Myc is a tran-
scriptional target of the Wnt/β-catenin, and activation of
the Wnt/β-catenin signaling pathway has been linked to
basal-like breast cancer [12,13].
The mammary epithelium consists of two layers: lu-
minal secretory cells and basal myoepithelial cells. Dur-
ing lactation, luminal cells produce and secrete milk in
response to hormone stimulation. In addition to the
above mentioned basal epithelial markers, myoepithelial
cells express smooth muscle (SM) contractile proteins,
such as α-SM-actin and SM-myosin. Various studies in
human and mouse models have suggested that multipo-
tent stem cells capable of regenerating the mammary
epithelium upon transplantation reside in the basal
myoepithelial layer [14-16]. Unipotent lineage-restricted
stem/progenitor cells have recently been identified by a
lineage-tracing approach [17,18]. Although the mecha-
nisms controlling the functions of mammary stem cells
currently are understood only partly, several studies have
pointed to Wnt/β-catenin pathway. First, Wnt factors
have been shown to promote the self-renewal of mouse
mammary epithelial cells capable of gland regeneration
[19]. In addition, adult uni- and bipotent stem cells
responsive to Wnt/β-catenin signaling have recently
been described [17]. In human mammary epithelial cells,
activation of the Wnt/β-catenin pathway after PTEN
knockdown has been shown to induce the amplification
of the stem/progenitor compartment [20].
It remains largely unknown how Wnt/β-catenin signal-
ing promotes mammary stem cell expansion. A recent
study has revealed that a Wnt target, the G-protein-
coupled receptor Lrg5, is necessary for mammary stem
cell activity [21]. We have shown that another Wnt/β-
catenin target, Myc, is essential for mammary stem cell
function in normal adult gland homeostasis [22]. However,
it remains unknown, if Myc is required for mammary stem
cell amplification and tumorigenesis driven by β-catenin,
or, other effectors of Wnt/β-catenin signaling pathway can
substitute for Myc in the control of mammary stem cell
expansion and development of malignant breast lesions.
Here, we address this question using a genetic approach.
The transgenic K5ΔNβcat mice generated by our team
display a constitutive activation of Wnt/β-catenin signal-
ing due to the expression of a stabilized form of β-catenin
in the mammary basal cell layer and develop mammary
lesions resembling basal-like mammary carcinomas [23].
We show here that the stem cell pool is amplified in the
preneoplastic glands of K5ΔNβcat mice. Furthermore, wefound that Myc is required for this amplification and for
β-catenin-induced tumorigenesis.
Results
Constitutive activation of β − catenin signaling in
mammary basal cells induces triple-negative tumors
Female K5ΔNβcat mice develop mammary tumors with a
median latency of 10 to 11 months [23]. Focal ductal
hyperplasias, visible at early stages, progress to carcin-
omas, often presenting areas of squamous differentiation
(Figure 1A). The tumors are highly proliferative and con-
sist of cells positive for basal markers, including K5, K14
and p63, but negative for the smooth muscle proteins
characteristic of myoepithelial cells, such as α-SMA and
calponin (Figure 1B, Additional file 1: Figure S1A). These
tumors stain negative for estrogen and progesterone re-
ceptors (ER and PR; Figure 1C,D). Moderate levels of
ErbB2 were detected, but not higher than those found in
normal tissue (Additional file 1: Figure S1B).
Affymetrix microarray gene expression analyses of
K5ΔNβcat mouse mammary tumors and hyperplasias
confirmed their basal characteristics, with an upregula-
tion of basal genes and downregulation of luminal and
smooth muscle genes. Quantitative RT-PCR (qPCR) ana-
lyses confirmed the upregulation of basal markers, such
as Krt14, Trp63, Trp73, Cdh3 and Bcn, and downregu-
lation of the luminal genes Krt18, Esr1, Prlr and the
smooth muscle marker, Acta2, with respect to control
tissue (Figure 1E).
We performed a hierarchical clustering analysis of
control and K5ΔNβcat mice datasets with a previously
established basal gene signature [24]. We identified three
distinct sample groups, corresponding to normal tissue,
hyperplasia and tumors (Figure 1F). Most of the basal
genes investigated were upregulated in the mammary
tumors of K5ΔNβcat mice, whereas luminal genes were
downregulated. Moreover, a combined hierarchical clus-
tering analysis of our K5ΔNβcat dataset and datasets for
human breast cancer cell lines [25] or basal breast
tumors [26] showed a clustering of K5ΔNβcat tumors
with the basal breast cancer lines and basal-like breast
tumors (Additional file 2: Figure S2).
Altogether these results indicate that the constitutive
activation of β-catenin signaling in the mammary basal
cell layer induces tumors with gene expression profiles
similar to that of basal-like human breast carcinomas
and morphological similarities to malignant metaplastic
human breast lesions.
Myc is required for the formation of K5ΔNβcat tumors
Several previously identified β-catenin target genes, in-
cluding Myc, were upregulated in K5ΔNβcat tumors, as
shown by microarray and qPCR analyses (Figure 2B;
Additional file 3: Figure S3A). Of note, the expression of
Figure 1 (See legend on next page.)
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Figure 1 K5ΔNβcat mammary tumors display characteristics of basal-like tumors. A. Haematoxylin/eosin staining. B. Double
immunofluorescence analysis with anti-K5 (green) and anti α-SMA (red) antibodies; nuclei are stained with DAPI. C, D. Immunohistochemistry with
anti-ER (C) and anti-PR (D) antibodies. Arrow in C indicates the presence of normal ductal luminal cells positively stained for ER. Bar: 75 μm (B,C),
150 μm (A,D). E. qPCR analysis of representative basal and luminal genes. The graph shows mean values ± SEM for four control tissue and five
K5ΔNβcat tumor samples; p < 0.05. F. Cluster analysis of K5ΔNβcat tumors, for the subset of genes defining the basal cluster in mouse tumor
models (upper panel, [24]) and four luminal epithelial genes (lower panel). Data from 4 control mammary tissue, 5 hyperplasia and 11 tumor
samples from K5ΔNβcat female are shown.
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not altered in tumor tissue (Additional file 3: Figure S3A).
Ingenuity pathway analysis (IPA) of microarray data
showed that the Myc pathway was activated in K5ΔN βcat
tumors (Additional file 3: Figure S3B). We found that
Myc accumulated in the nuclei of tumor cells, often
co-localizing with the HA-tagged transgenic protein
(Figure 2A), and the upregulation of several Myc target
genes in K5ΔN βcat tumors was confirmed by qPCR
(Figure 2B).
To study whether Myc contributed to K5ΔN βcat
mammary tumor formation, we conditionally deleted
Myc gene from the basal cell layer of K5ΔN βcat mice
by crossing them with mice carrying conditional alleles
for Myc (MycF/F) and K5Cre mice. Cohorts of K5ΔN
βcat, K5ΔN βcat; K5Cre; MycF/+ and K5ΔN βcat; K5Cre;
MycF/F females were monitored for tumor formationFigure 2 Myc is necessary for mammary tumor formation in K5ΔNβca
tumor with anti-HA (red), and anti-Myc (green) antibodies. Arrows indicate
analysis of Myc target genes. The graph shows mean ± SEM for four contro
tumor-free survival curve of K5ΔNβcat virgin and parous mice. 17 virgin an
and 12 virgin and 10 parous K5ΔNβcat; K5Cre;MycF/F females were analyzeduntil the age of 15 months (Figure 2C). In 90-95% of
K5ΔN βcat females, palpable mammary tumors developed
with a mean latency of 11 and 9.6 months for virgin and
parous females, respectively. In contrast, only less than
half of the females heterozygous for Myc in basal cells
(K5ΔN βcat; K5Cre; MycF/+) developed tumors (Figure 2C).
Furthermore, tumor latencywasdelayed (14 and11.2months
for virgin and parous females respectively), and the number
of tumors per animal was reduced, when compared to
K5ΔNβcat females (Table 1).
Strikingly, regardless of parity, none of the females with
Myc-deficient basal cells (K5ΔN βcat; K5Cre; MycF/F) devel-
oped palpable mammary tumors. Moreover, whole-mount
mammary gland analysis revealed the absence of hyper-
plasia in K5ΔN βcat; K5Cre; MycF/F females (Figure 3A).
Thus, Myc is required for mammary tumor formation in
K5ΔNβcat mice.t animals. A. Double immunofluorescence analysis of a K5ΔNβcat
the presence of nuclei positively stained for Myc. Bar: 40 μm. B. qPCR
l tissue and five K5ΔNβcat tumor samples; p < 0.05. C. Kaplan-Meier
d 10 parous K5ΔNβcat, 14 virgin and 6 parous K5ΔNβcat;K5Cre;MycF/+
.
Table 1 Tumor incidence in K5ΔNβcat and K55ΔNβcat;
K5Cre; MycF/W+mice
Genotype K5ΔN βcat K5ΔN βcat;
K5Cre; MycF/+
Animals with tumor/total animals 25/29 8/20
Animals with 2 or more tumors 16 2
Animals were sacrificed at the age of 16 months.
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signaling is mediated by Myc
As described previously, the mammary lesions observed
in K5ΔNβcat females consist essentially of basal epithe-
lial cells that lack myoepithelial differentiation [23]. We
hypothesize that these lesions might result from an
amplification of stem/progenitor cells in the mammary
basal cell layer, due to Wnt/β-catenin signaling involv-
ing Myc activation. To investigate changes in stem cell
activity in mutant mice, we isolated basal cells from 10-
month-old virgin control, K5ΔNβcat and K5ΔN βcat;
K5Cre; MycF/F females using flow cytometry cell sorting.
Only K5ΔN βcat females with no palpable mammary tu-
mors were chosen for these experiments. Whole-mount
analysis revealed mild to moderate hyperplasia in most
K5ΔN βcat mouse glands at this age (Figure 3A). Al-
though the CD24 expression was up regulated in theFigure 3 Deregulated β-catenin signaling induces the expansion of th
mary glands from 10-month-old mice. Bar: 3 mm. B. Separation of luminal
thelial cell populations from 10-month-old mice. C. qPCR analysis of Myc ex
populations from 10-month-old virgin mice. D. Percentage of basal cells w
experiments; *p < 0.05; **p < 0.001).basal cell population of K5ΔN βcat mouse glands,
two epithelial cell populations — luminal (CD24+/
CD49flow) and basal (CD24+/CD49fhigh) — were effi-
ciently separated (Figure 3B). We checked the purity of
populations by qPCR analyses of K14 and K18 (basal and
luminal keratins, respectively) in the sorted populations
(Additional file 4: Figure S4). Analysis of gene expression
confirmed the deletion of Myc from the basal cell popu-
lation of K5ΔN βcat; K5Cre; MycF/mice (Figure 3C).
Basal cells accounted for 37.8 ± 6% of the total mam-
mary epithelial cell population in control mice and 53.4 ±
3.5% in K5ΔN βcat mice, indicating an amplification of
the basal cell compartment induced by the activation of
β-catenin signaling (Figure 3D). By contrast, in mutants
presenting Myc deletion from the basal cell layer, K5ΔN
βcat; K5Cre; MycF/F mice, the mammary basal compart-
ment was smaller, accounting for only 23.4 ± 1.5% of the
total mammary epithelial cells population (Figure 3D).
To analyze the mammary stem/progenitor population,
sorted basal cells were first tested in two-dimensional
colony-formation assays [15]. The number of colony-
forming cells was 1.8 times higher in K5ΔNβcat females
than in controls (Figure 4A). The colonies displayed
higher levels of cell proliferation, as determined by BrdU
incorporation analysis, the percentage of BrdU-positivee basal cell population. A. Whole-mount carmine staining of mam-
(blue ovals, CD24+/CD49low) and basal (red ovals, CD24+/CD49high) epi-
pression in freshly isolated basal (B) and luminal (L) mammary cell
ithin the epithelial cell compartment (mean ± SEM of 3 independent
Figure 4 Myc is required for stem cell amplification induced by deregulated β-catenin signaling. A. Clonal colonies formed by 1000
sorted mammary basal cells. The graph shows the percentage of clonogenic cells (mean ± SEM of 3 independent experiments; *p < 0.01). B.
Sphere formation by sorted basal cells. The graph shows the percentage of sphere-forming cells (mean ± SEM of 3 independent experiments;
*p < 0.01). Bar: 100 μm. C. Mammary epithelial outgrowths developed from 1000 mammary basal cells transplanted into the cleared mammary fat
pads. Bar: 4 mm. D. qPCR analysis of proliferation-related genes. Basal cell samples from K5ΔNβcat;K5Cre;MycF/F and control mice obtained in 3
independent sorting experiments were analyzed.
Table 2 Limiting dilution transplantation of mammary
basal cells from control and K5ΔN βcat mice





Repopulating unit frequency in the basal cell population, as determined in
limiting dilution transplantations: 1/66 (1/134-1/32) for control and 1/14 (1/23-
1/8) for K5ΔNβcat; 95% CI, p value = 0.000284.
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K5ΔN βcat cells (p < 0.03; data from three independent
cell sorting experiments). Basal cells isolated from K5ΔN
βcat; K5Cre; MycF/F females were unable to form col-
onies (Figure 4A).
Sorted mammary epithelial cells have been reported to
form mammospheres when cultured in the presence of
2% Matrigel, a property attributed to stem and progeni-
tor cells [27]. As shown in Figure 4B, K5ΔN βcat basal
cells formed four times more mammospheres than con-
trol cells, and the absence of Myc completely prevented
mammosphere formation.
To further analyze the mammary stem/progenitor cell
activity in mutant mice we transplanted sorted mam-
mary basal cells at limiting dilutions (from 500 to 10
cells) into the cleared fat pad of prepubertal mice(Table 2). In all cases, basal cells from K5ΔN βcat glands
produced normal mammary outgrowths with no tumor
development (Figure 4C). The repopulating unit fre-
quency of the basal population was 1/66 (1/134-1/32)
for controls and 1/14 (1/23-1/8) for mutants (Table 2).
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frequency of functional stem cells in the mammary basal
cell layer by a factor of five. Basal cells from K5ΔNβcat;
K5Cre; MycF/F mice generated no mammary outgrowths
upon transplantation even, when 2000 cells were trans-
planted (Figure 4C).
We recently showed that Myc deletion from the mam-
mary basal cell layer affects stem cell activity [22]. Consist-
ent with data for other tissues [7,28] microarray analysis
of Myc-deficient mammary basal cells showed impaired
expression of numerous genes involved in important cell
functions, including metabolism, replication, protein syn-
thesis and the cell cycle, relating to the capacity of the cell
to proliferate (Additional file 5: Table S1). Many of these
genes were deregulated in the mammary tumors devel-
oped by K5ΔNβcat mice (Additional file 6: Table S2).
Interestingly, about half of these genes (40 out of 85) were
found to be upregulated in the basal-like human breast
tumors [26], (Additional file 6: Table S2). The expression
of a set of proliferation-related genes upregulated in
K5ΔNβcat tumors was analyzed by qPCR in mammary
basal cells from K5ΔNβcat;K5Cre;MycF/F mice and control
basal cells. In the absence of Myc, these genes were down-
regulated (Figure 4D), suggesting that Myc deletion im-
peded β-catenin-induced tumorigenesis, probably by
restricting the acute growth program required for the
amplification of basal progenitors and tumor formation.
Discussion
We show here that constitutive stimulation of β-catenin
signaling in the mammary basal cell layer of transgenic
mice, led to development of triple-negative tumors that
required activation of the Myc pathway. These tumors
displayed transcriptional profile resembling that of
human breast basal-like carcinomas and presented mor-
phological similarities with metaplastic breast carcin-
omas, a basal-like tumor subtype [6].
Notably, K5ΔNβcat mammary tumors are different from
those developing in MMTV-ΔN89βcat and MMTV-Wnt1
mice suggesting different cellular and molecular mecha-
nisms underlying tumorigenesis. In MMTV-ΔN89βcat
mice, luminal ER- tumors are thought to develop due to
activation of β-catenin signaling in luminal progenitors,
whereas in MMTV-Wnt1 model, “mixed” tumors contain-
ing luminal ER + and myoepithelial cells were suggested to
originate from stem cells [29,30]. We show here that, as
assessed in mammosphere and transplantation assays, in
K5ΔNβcat mice, a basal stem/progenitor cell population is
amplified at the early stages of malignancy, before the for-
mation of basal-like invasive tumors with metaplastic
characteristics.
The differences between breast tumor subgroups were
hypothesized to reflect different types of mutation lead-
ing to tumorigenesis, or different cells of origin [31].Two independent studies have indicated that basal-like
Brca1-associated human and mouse mammary tumors
originate from luminal epithelial progenitors [14,32].
The transformation of primary human breast basal-type
epithelial cells has been reported to result in the devel-
opment of metaplastic tumors [33]. Therefore, in light of
our results, it is tempting to suggest that metaplastic
basal-like breast tumors with squamous differentiation
originate from basal progenitors or cells that acquired
stem/progenitor properties due to enhanced β-catenin
signaling. Of note, mammary lesions developed in
K5ΔNβcat mice, consist of tumor cells that, in contrast
to basal myoepithelial cells, do not express SM markers,
suggesting that β-catenin activation either prevented SM
differentiation of undifferentiated progenitors, or induced
dedifferentiation of myoepithelial cell and acquisition of a
progenitor phenotype, resulting in accumulation of basal
cells with stem/progenitor properties. Transition between
non-stem and stem-like states has been described in cul-
tured human mammary basal epithelial cells [34]. More-
over, enhanced Wnt signaling in the intestinal epithelium
has been found to induce dedifferentiation of non-stem
cells and acquisition of tumor-initiating capacity [35].
Further studies involving the use of genetic markers of
differentiated myopithelial cells are required to identify
within the mammary basal compartment, the cell at the
origin of K5ΔNβcat mouse tumors.
Genes encoding Myc and CyclinD1, two important
Wnt targets, are often amplified and/or up-regulated in
breast cancer [36]. Confirming previous analysis of pre-
neoplasic glands [23], we have not found a significant
up-regulation of Cyclin D1 in K5ΔNβcat tumors. This
result is in agreement with previous studies reporting
that Cyclin D1 is dispensable for Wnt or β-catenin
induced tumorigenesis [37,38]. In K5ΔNβcat mammary
tumors, similarly to previous findings in intestinal tumor
models [39], Myc pathway appears activated and indispens-
able for β-catenin induced tumorigenesis. Interestingly, dif-
ferent studies have identified a Myc transcriptional gene
signature to be associated with the basal-like breast cancer
subtype [9-11]. In addition, Myc signaling has been shown
to be upregulated in high-grade mammary tumors with
presumptive cancer stem cell properties [40,41]. Therefore,
Myc-targeting therapies are thought to be promising for
specific treatment of different breast tumors [42]. The dir-
ect Myc inhibition seems difficult, and strategies used to
target Myc include approaches focused on tumor cell meta-
bolic abnormalities induced by Myc overexpression [43] or
synthetic-lethal strategy [10,44]. A recent study has shown
that cyclin-dependent kinase inhibition leads to regression
of triple-negative tumors with Myc activation [10].
We have recently shown that Myc is essential for
mammary stem cell activity [22]. In agreement with pre-
vious reports [7], microarray analysis of Myc deficient
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genes involved in essential cell functions converging on
the capacity of the cell to proliferate. An important part
of these genes are upregulated in the K5ΔNβcat mam-
mary tumors. Thus, our results indicate that Myc acts as
the ultimate downstream effecter of β-catenin to provide
the enhanced proliferative capacity to basal stem/progeni-
tor cells leading to their amplification and tumorigenesis
and preventing the myoepithelial differentiation (Figure 5).
One important question to address in future studies is
whether Myc deletion from established K5ΔNβcat tumors
would lead to tumor regression. Such experiments would
require inducible promoters permitting efficient gene dele-
tion at desired time points.
In conclusion, our work provides new insights into the
possible contribution of stem/progenitor cells to breast
tumorigenesis and further confirms that the Myc path-
way can be an interesting target for the development of
basal-like breast cancer-tailored therapies.Figure 5 Hypothetical scheme on the effects of β-catenin
signaling activation on stem/progenitor population and tumor
induction. A. During normal homeostasis, basal and luminal
progenitors with limited self-renewal potential, maintain their
respective lineages. B. Constitutive activation of β-catenin signaling
leads to enhanced basal progenitor self-renewal and expansion
preventing myoepithelial differentiation and giving rise to basal-like
tumors. Both, basal progenitor amplification and tumorigenesis
are Myc-dependent.Methods
Mice
K5ΔNβcat, K5Cre and MycF/F mice have been previously
described [22,23,45-47]. All mice were bred in a 129SV/
C57BL6 genetic background. Experiments were con-
ducted in accordance with French veterinary guidelines
and those of the Council of Europe for animal experi-
mentation (L358-86/609EEC).
Microarray analysis
Total RNA was extracted from mammary tissue with
Trizol Reagent (Invitrogen), treated with DNAse and
cleaned up on RNAeasy microcolumns (Qiagen). RNA
was isolated from sorted basal cells in three independent
biological pools of four to six control or mutant mice
with the RNAeasy Microkit (Qiagen). Quality control
was performed with an Agilent 2100 Bioanalyzer and the
RNA 6000 Pico total RNA Kit (Agilent Technologies).
As previously described [48], the WT-Ovation™ Pico
RNA Amplification System and FL- Ovation™ cDNA
Biotin Module V2 (Nugen) were applied to 1 ng of total
RNA from sorted cells to generate biotinylated cDNA.
Microarray analysis was carried out with Affymetrix
GeneChip Mouse Genome 430 2.0 arrays. Expression
data were normalized with the MicroArray Suite v.5.0
(MAS 5.0) algorithm and analyzed with the Partek
Genomics Suite (Partek Incorporated). Differences in gene
expression were considered to be validated whenever, for
each ratio, the higher median gene expression value was
up to 30 (corresponding to the estimated background cut-
off, data not shown) and the corresponding fold-change
was greater than 2. The microarray data have been depos-
ited in the NCBI Gene Expression Omnibus and are ac-




Hierarchical clustering analysis was carried out with Partek
Genomics Suite Software (Partek, Inc.). The molecular and
functional interactions of the genes identified were also
analyzed with Ingenuity pathways analysis (IPA) tools
(Ingenuity® Systems) and a gene ontology approach (http://
david.abcc.ncifcrf.gov). To compare the mouse and the hu-
man datasets, after GCRAMA normalization with Partek, a
common correspondence between the mouse and human
genes, was performed by using the annotation Tools pack-
age 2.35-8 in R 2.11.1 software and the HomoloGene data-
base (ftp://ftp.ncbi.nlm.nih.gov/pub/HomoloGene).
qPCR analysis
RNA was reverse-transcribed with MMLV H(−) Point
reverse transcriptase (Promega), and quantitative PCR
was performed by real-time monitoring of the increase
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Sequence Detection System (Applied Biosystems). The
values obtained were normalized to Gapdh levels. The
primers used for qPCR analysis are listed in Additional
file 7: Table S3.
Preparation of mammary epithelial cells and
cell sorting analysis
The inguinal mammary glands of four to five females or
hyperplastic mammary samples from two K5ΔNβcat fe-
males were pooled for the preparation of single-cell sus-
pensions and cells were processed for flow cytometry as
previously described [16,49]. The following conjugated
antibodies were used: anti-CD24-PE (clone M1/69; BD
Pharmingen), anti-CD49f-FITC (clone GoH3; BD Phar-
mingen), anti-CD45-APC (clone 30-F11; Biolegend), anti-
CD31-APC (clone MEC13.3; Biolegend). Labeled cells
were analyzed and sorted on a FACSVantage flow cyt-
ometer (Becton Dickinson, San Jose, CA, USA). Sorted
cell populations were routinely reanalyzed and found to
be 94 to 98% pure. Cell viability after sorting, as estimated
by trypan blue exclusion, was between 80 and 90%.
Transplantation assays
Sorted basal cells were resuspended in 10 μl of 50%
growth factor-reduced Matrigel (BD Bioscience) and
injected into the inguinal fat pads of three-week-old
nude Balb/c females cleared of endogenous epithelium,
as described elsewhere [49]. Mutant and control cells
were grafted into contralateral fat pads of the same re-
cipient mouse and outgrowths were analyzed 10 weeks
after transplantation. Repopulating unit frequency was
calculated with Extreme Limiting Dilution Analysis soft-
ware [50].
Cell culture assays
Sorted basal cells were cultured in DMEM/F12 medium
containing 1% FCS and B27 supplement, at a density of
1000 cells per well [15]. For suspension sphere culture,
sorted basal cells were plated on 24-well ultralow-
attachment plates at 5000 cells/well and cultured in
DMEM/F12 media containing B27, EGF, bFGF, heparin
and 2% growth factor-reduced Matrigel (BD Bioscience,
[27]. ImageJ software was used for quantification.
Whole-mount analyses, histology and immunolabeling
Dissected mammary fat pads were spread onto glass slides,
fixed in a 1/3/6 mixture of acetic acid/chloroform/metha-
nol and stained with carmine (whole-mount staining). For
histological analysis, samples were embedded in paraffin.
Sections (7 μm thick) were cut and dewaxed for haema-
toxylin/eosin staining or immunolabeling, as previously
described [23]. The following primary antibodies were
used: mouse monoclonal anti-α-smooth muscle actin,anti-K14 (Sigma), anti-K8 (Covance) and anti-oestrogen
receptor α (Dako); rat monoclonal anti-HA (Roche); rabbit
monoclonal anti-calponin (Epitomics), polyclonal anti-K5,
(Covance), anti-Ki67 (Novocastra), anti-c-erbB2, anti c-
Myc and anti-PR (sc-284, sc-764 and sc-7208, respectively,
Santa Cruz Biotechnologies). Alexafluor-conjugated sec-
ondary antibodies (1/1000, Molecular Probes) were used
for immunofluorescence labelling. The Envision + System
HRP kit (Dako) was used for immunohistochemistry.
Statistical analysis of the data
All values are shown as mean ± standard error of the
mean (SEM). P values were determined using Student’s
test with two-tailed distribution and unequal variance.
Additional files
Additional file 1: Figure S1. Immunohistological analysis of K5ΔNβcat
mammary tumors. A. Double immunofluorescence with antibodies
against: K14 (red) and calponin (green) left panel; K5 (red) and K8 (green),
central panel; HA (red) and Ki67 (green), right panel. B.
Immunohistochemistry with the antibody against ErbB2 in normal
mammary tissue (left) and a K5ΔNβcat hyperplasia (right). Bar: 75 μm (A),
150 μm (B).
Additional file 2: Figure S2. Unsupervised hierarchical clustering of
K5ΔNβcat tumor data with a dataset obtained from human breast cancer
cell lines (A, ref. [25]) and breast tumors (B, Ref. [26]).
Additional file 3: Figure S3. Gene expression analysis of K5ΔNβcat
mammary tumors. A. Q-PCR analysis of Wnt/β-catenin pathway targets.
The graph represent the mean values ± S.E.M. of four control tissue and
five K5ΔNβcat tumor samples; p < 0.05. B. Ingenuity pathway analysis
(IPA) of Myc pathway in K5ΔNβcat mammary tumors. The genes whose
expression is increased in tumors with respect to normal mammary tissue
are shown in red, and those whose expression is decreased, in green.
Additional file 4: Figure S4. Q-PCR analysis of Krt14, and Krt18 in
freshly isolated basal (B) and luminal (L) cell populations from ten month-
old virgin control, K5ΔNβcat and K5ΔNβcat; K5Cre;MycF/F mouse mam-
mary glands (the cell sorting experiment shown in Figure 3B).
Additional file 5: Table S1. GOstat analysis of genes downregulated in
Myc-deficient basal cells.
Additional file 6: Table S2. GO analysis of the genes downregulated in
Myc-deficient basal cells and upregulated in K5ΔNβcat hyperplasia.
Additional file 7: Table S3. Primers used for qPCR analysis.
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